34TH GENERAL ANNUAL MEETING OF THE BELGIAN HEMATOLOGY SOCIETY

Final Programme
1-2 FEBRUARY 2019
Dolce La Hulpe, Brussels

www.bhs.be
At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone.

Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.
Dear colleagues,

Welcome to the **34th General Annual Meeting of the BHS in Dolce La Hulpe**.

We have selected several high-level scientific presentations which will cover the diagnostic approach, current recommendations for the treatment of hematologic diseases as well as new developments in the field.

This year, we will continue the success story of the “Ethics and Economy” session with a special presentation on ethical implications of incidental findings in next generation sequencing. In the third edition of the “Advances in laboratory technology” session, two major topics will be discussed: gene therapy in haemophilia and the impact of gut microbiota. We will also taste of high quality clinical topics as multiple myeloma and belgian guidelines, histiocytosis, Acute myeloid leukemia, pregnancy and cancer and the discussion of the possibility to cure chronic lymphocytic leukemia by Professor Michael Hallek during the “Pierre Stryckmans Lecture”. Research is once again highlighted during the selected oral presentations, the commented poster walk and the awards for young researchers.

For several years the “Nurse symposium” has become a must at our meeting and it is with great enthusiasm that we will welcome them once again on Friday.

I wish you an inspiring congress!

On behalf of the board,

Nathalie Meuleman  
President BHS

---

### PROGRAM GENERAL ANNUAL MEETING  
**FRIDAY 1 FEBRUARY 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Registration</td>
</tr>
</tbody>
</table>
| 08.45 - 09.00| Welcome  
**Prof. Nathalie Meuleman, President BHS**                              |
| 09.00 - 09.30| **Highlight 1:**  
Chairs: Chantal Doyen & Nathalie Meuleman  
Belgian treatment guidelines 2019 for multiple myeloma  
**Prof. Marie-Christiane Vekemans, Cliniques universitaires Saint Luc (UCL), Brussels** |
| 09.30 - 10.30| **Advances in laboratory technology**  
Chairs: Barbara Cauwelier & Ivan Van Riet  
**09.30** Gene therapy for haemophilia: recent preclinical and clinical advances  
**Prof. Thierry VandenDriessche, Vrije Universiteit Brussel, Brussels**  
**10.00** The gut microbiota  
**Prof. Laure Bindels, Louvain Drug Research Institute, Brussels** |
| 10.30 - 11.00| Coffee break                                                        |
| 11.00 - 11.30| **Special lecture 1:**  
Chairs: Marie-Christiane Vekemans & Dominiek Mazure  
Histiocytoses: inflammatory or neoplastic diseases?  
**Prof. Julien Haroche, Hôpital de la Pitié Salpêtrière, Paris, France** |
| 11.30 - 12.30| **Satellite session 1 sponsored by Gilead**  
“CAR-T cell approaches in Aggressive B Cell Lymphoma”  
**Chair: Prof. Peter Vandenberghe, UZ Leuven**  
**11.30** Clinical overview of anti-CD19 CAR-T cell therapy in DLBCL  
**Prof. Catherine Thieblemont, Hôpitaux Universitaires Saint-Louis, Paris**  
**12.00** Patient management before, during and after CAR-T treatment in aggressive lymphoma  
**Dr. Reuben Benjamin, King’s College Hospital, London** |
| 12.30 - 13.30| Lunch and Commented Poster Walk 1                                   |
| 13.30 - 15.00| **Selected oral abstracts**  
**Chairs: Dimitri Breems & Chantal Doyen**  
**13:30** A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stromal cells after myeloablative or nonmyeloablative conditioning in patients with hematological malignancies  
**A. De Becker**  
**13:45** Unraveling the landscape of copy number aberrations in Hodgkin lymphoma: a joint KU Leuven and LYSA study on circulating cell-free DNA  
**L. Buedts** |

---

**www.bhs.be**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>Welcome</td>
<td>Martine Heylens Chair Nurses committee</td>
</tr>
<tr>
<td>09.00</td>
<td>Living with haemophilia: from toddler till young adult woman!</td>
<td>Noémie Colasuonno, the patient perspective</td>
</tr>
<tr>
<td></td>
<td>Wanting to have children and being a haemophilia patient</td>
<td>Patrick Desmet, the patient perspective</td>
</tr>
<tr>
<td>09.45</td>
<td>Adolescents/young adults and their caregiver on the onco-hematology ward</td>
<td>Johan De Munter &amp; Marijke Quaghebeur, UZ Gent, Gent</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>Hurdies and challenges of CART-therapy in children with acute lymphoblastic leukemia</td>
<td>Prof. Barbara De Moerloose, UZ Gent, Gent</td>
</tr>
<tr>
<td>11.45</td>
<td>Haploidentical stem cell transplantation: state of the art anno 2019</td>
<td>Dr. Dominik Selleslag, AZ St. Jan Brugge, Brugge</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13.30</td>
<td>Adherence to oral anticancer drugs</td>
<td>Anneleen Vanhellemont, UZ Leuven, Leuven</td>
</tr>
<tr>
<td>14.00</td>
<td>Fertility preservation before cancer treatment</td>
<td>Prof. Marie-Madeleine Dolmans, Cliniques universitaires Saint Luc (UCL), Brussels</td>
</tr>
<tr>
<td>14.30</td>
<td>The use of antifungal drugs in immunocompromised patients</td>
<td>Dr. Anne Sonet, CHU UCL Namur (Godinne), Yvoir</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td>Ethics and Economy:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Kristel Buvé &amp; Samantha Benghiat</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ethic, legal and social implications of next generation sequencing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction by Prof. Veerle Labarque, UZ Leuven, Leuven</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presentation by Prof. Pascal Borry, UZ Leuven, Leuven</td>
<td></td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>Pierre Stryckmans Lecture:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Nathalie Meuleman &amp; Marie-Christiane Vekemans</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction by: Prof. Ann Janssens, UZ Leuven, Leuven</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is there a curing menu for chronic lymphocytic leukemia?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof. Michael Hallek, University Hospital Cologne, Köln, Germany</td>
<td></td>
</tr>
<tr>
<td>18.00-19.00</td>
<td>Reception + Commented Poster Walk 2</td>
<td></td>
</tr>
<tr>
<td>19.00</td>
<td>Congress dinner (additional registration necessary)</td>
<td></td>
</tr>
</tbody>
</table>
08.30 - 09.00 GENERAL ASSEMBLY - (access for BHS members only)

09.00 - 10.00 Satellite session 2 sponsored by Pfizer
Chair: Prof. Johan Maertens, UZ Leuven
09.00 Moving beyond 7+3 for treatment of first line acute myeloid leukemia
Prof. Sylvie Castaigne, Centre Hospitalier de Versailles, Université de Versailles Saint-Quentin, Le Chesnay, France
09.30 Management considerations in treating relapsed or refractory acute lymphoblastic leukemia with an antibody-drug conjugate
Prof. David Marks, University Hospitals Bristol, National Health Service Foundation Trust, Bristol, United Kingdom

10.00 - 11.00 Highlight 2: Pregnancy and Cancer
Chairs: Veerle Labarque & Sophie Servais
10.00 Fertility preservation for young patients with cancer: who is at risk and what can be offered?
Prof. Michel De Vos, UZ Brussel, Brussels
10.30 Cancer treatment for haematological malignancies during pregnancy: safe? efficacious?
Prof. Frederik Amant, UZ Leuven, Leuven, Belgium and Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, the Netherlands

11.00 - 11.30 Coffee break

11.30 - 12.30 Satellite session 3 sponsored by Takeda
11.30 Therapeutic options for penta-refractory and high risk multiple myeloma patients.
Dr. Rakesh Popat, University College London Hospital, London, United Kingdom
12.00 Managing Hodgkin lymphoma in transplantation ineligible patients
Dr. Pauline Brice, Hôpitaux Universitaires Saint-Louis, Lariboisière, Paris, France

12.30 - 13.00 Awards for best oral and poster presentations
Presentations projects PACE Awards 2017
Presentations projects PACE Awards 2018
13.00 Election results and Closing Remarks
GENERAL INFORMATION

Registration via website www.BHS.be

REGISTRATION FOR THE GENERAL ANNUAL MEETING 2019

FEES

Before 22/12/2018  After 22/12/2018 and on-site

General Annual Meeting
BHS member (MD hematologists, MD specialists, Senior scientists) EUR 125,00  EUR 150,00
BHS junior member (MD trainees, PhD students) EUR 75,00  EUR 100,00
Non-member GAM meeting* EUR 250,00  EUR 300,00

Nurse Meeting
BHS associate member EUR 35,00  EUR 40,00
Non-member EUR 45,00  EUR 55,00

* MD hematologists, MD specialists, Senior scientists, MD trainees, PhD students

PLEASE NOTE
Only approved 2018 BHS members (and membership applications before December 1st) are entitled to register for the GAM at the discounted member registration fee. Payment of your 2018 membership fee should be settled before January 1st, 2019!

CANCELLATION
Cancellations and refund requests must be submitted in writing to the congress secretariat. Cancellations made before 8 January 2019 will be refunded less 35 euro to cover administration costs. After this date no refunds will be given. All refunds will be made after the congress.

ELECTIONS OF BOARD MEMBERS
Only regular members are allowed to vote. Information on e-voting will be send to members before the end of January.

ACCREDITATION
Accreditation for the General Annual Meeting is pending with specific accreditation for Ethics and Economy.

EXHIBITION
A technical and pharmaceutical exhibition will be organized in conjunction with the annual meeting of the Belgian Hematology Society.

TRANSLATION
Simultaneous translation will be available for the Nurse meeting.

BHS EVENTS APP

Download instructions
The APP can be downloaded from the App Store and Google Play store. If you have not downloaded the BHS Events App yet, you will need to download that App first.
1. Download the BHS Events App
2. After completion: install BHS GAM 2019 into the BHS Events App
3. In case the App is already installed on your mobile device, please install the update

THE BHS GAM 2019 APP IS SPONSORED BY:

Novartis
THE TOUGHEST CANCERS ARE RESISTANT.

WE MUST BE PERSISTENT.

AT AMGEN ONCOLOGY, WE ARE FACING CANCER’S TOUGHEST CHALLENGES.

35 years of innovation by unlocking the world’s best science

10 oncology therapies providing targeted treatment and supportive care

1 mission to serve patients through our commitment to oncology

With a heritage in pioneering groundbreaking therapies, Amgen Oncology is working to solve the tough cancer mysteries so that you can be better armed against today’s fiercest cancers.